NEW YORK (GenomeWeb) – In a filing with the US Securities and Exchange Commission, MBio Diagnostics said it is offering for sale $2.3 million of stock and warrant units.

The units consist of 10,000 shares of Series B-2 preferred stock and 10,000 warrants to purchase Series B-2 preferred stock. The company noted it has already raised $562,500, and plans to raise $1.7 million more.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.